Research Topics
Genomes and Genes | Peter Paul De DeynSummaryCountry: Belgium Publications
| Collaborators
|
Detail Information
Publications
Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group studyPeter Paul De Deyn
Department of Neurology, Middelheim Hospital and Laboratory of Neurochemistry and Behaviour, Department of Biomedical Sciences, Institute Born Bunge, University of Antwerp, Antwerp, Belgium
Int J Geriatr Psychiatry 27:296-304. 2012....
Risperidone in the management of agitation and aggression associated with psychiatric disordersPeter Paul De Deyn
Department of Neurology, Middelheim Hospital and Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences, Born Bunge Foundation, University of Antwerp UA, Universiteitsplein 1, 2610 Antwerp Wilrijk, Belgium
Eur Psychiatry 21:21-8. 2006..This review provides an overview of the prevalence and treatment of agitation and aggression, and focuses on the use of risperidone to treat these symptoms in patients from different age groups...- Prevalence and incidence of dementia among 75-80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: the Antwerp Cognition (ANCOG) StudyP P De Deyn
Department of Neurology and Memory Clinic, Middelheim General Hospital, ZNA, Antwerp, Belgium
Clin Neurol Neurosurg 113:736-45. 2011.... - Guanidino compounds as uremic (neuro)toxinsPeter Paul De Deyn
Department of Neurology, ZNA Middelheim Hospital and Memory Clinic Antwerp, Institute Born Bunge, University of Antwerp, Belgium
Semin Dial 22:340-5. 2009..In this article, we review the uremic GCs with particular attention to their neurotoxicity. We elaborate in detail on the mechanisms of action of the neurotoxic uremic GCs and summarize the kinetics of these toxins... - Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidonePeter Paul De Deyn
Department of Neurology, Memory Clinic, Middelheim Hospital, ZNA, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk Antwerp, Belgium
Clin Neurol Neurosurg 107:497-508. 2005.... 
Modest phenotypic improvements in ASA-deficient mice with only one UDP-galactose:ceramide-galactosyltransferase geneS Franken
Department of Physiological Chemistry, University of Bonn, Germany
Lipids Health Dis 5:21. 2006..This deficiency is known to lead to a decreased synthesis of galactosylceramide and sulfatide, which should reduce sulfatide storage and improve pathology in ASA-deficient mice...- More advanced Alzheimer's disease may be associated with a decrease in cerebrospinal fluid pressurePeter Wostyn
Department of Psychiatry, PC Sint Amandus, Reigerlostraat 10, 8730 Beernem, Belgium
Cerebrospinal Fluid Res 6:14. 2009..This could result in an abnormally high trans-lamina cribrosa pressure difference and lead to glaucomatous damage... - Evaluation of the APP23-model for Alzheimer's disease in the odour paired-associate test for hippocampus-dependent memoryAnnemie Van Dijck
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, University of Antwerp, Department of Biomedical Sciences, Universiteitsplein 1, Wilrijk, Belgium
Behav Brain Res 190:147-51. 2008..Possible explanations for this discrepancy with earlier published results are the advanced age of the mice or the C57Bl/6J background, in which the model was established... - Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 modelDebby Van Dam
Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Department of Biomedical Sciences, Universiteitsplein 1, B-2610 Wilrijk, Belgium
Eur Neuropsychopharmacol 16:59-69. 2006..This is the first study reporting disease-modifying efficacy of galantamine and memantine in transgenic mice modeling Alzheimer's disease... - Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's diseaseDebby Van Dam
Department of Biomedical Sciences, Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Psychopharmacology (Berl) 197:37-43. 2008.... - Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression modelEllen Vloeberghs
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium
Behav Neurosci 122:491-7. 2008..Our results suggest the presence of a hypermetabolic state in this model. This is the first report, evidencing the presence of changes in eating and drinking behavior in a single transgenic Alzheimer mouse model... - Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categoriesMarcel J H Aries
Department of Neurology and Memory Clinic, Middelheim and Hoge Beuken General Hospitals ZNA, University of Antwerp, Antwerp, Belgium
Int J Geriatr Psychiatry 25:1186-95. 2010..To study frontal lobe symptoms in relation to dementia severity within and across diagnostic dementia categories, a cross-sectional analysis of behavioural data was performed... - No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's diseaseSebastiaan Engelborghs
Department of Neurology and Memory Clinic, Middelheim General Hospital ZNA, Antwerpen, Belgium
Brain 130:2320-6. 2007.... - Biochemical and behavioural phenotyping of a mouse model for GAMT deficiencyAn Torremans
Laboratory of Neurochemistry and Behaviour Born Bunge Foundation, University of Antwerp, Department of Biomedical Sciences, Universiteitsplein 1, 2610 Antwerp Wilrijk, Belgium
J Neurol Sci 231:49-55. 2005..KO mice displayed mild cognitive impairment. In general, it could be concluded that the GAMT mouse model is very useful for biochemical research of GAMT deficiency, but shows only a mild cognitive deficit... - APP23 mice display working memory impairment in the plus-shaped water mazeEllen Vloeberghs
Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium
Neurosci Lett 407:6-10. 2006..The transgenic mice had slower learning curves; however, consolidation of the learned information appeared intact in this learning paradigm. This report demonstrates impairment of working memory in this transgenic Alzheimer model... - Mood and male sexual behaviour in the APP23 model of Alzheimer's diseaseEllen Vloeberghs
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, B 2610 Wilrijk, Belgium
Behav Brain Res 180:146-51. 2007..The present study nevertheless provides evidence that the APP23 mice are more anxious and fearful in comparison with control littermates, which opens perspectives to future treatment studies... - Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS)Debby Van Dam
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, B 2610 Wilrijk, Belgium
Behav Brain Res 162:233-9. 2005..The age-dependent cognitive decline and neuromotor disturbances may be related to the progressive cognitive and behavioural difficulties observed in FXTAS patients... - Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviourEllen Vloeberghs
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium
Arzneimittelforschung 58:265-8. 2008.... - Aggressive male APP23 mice modeling behavioral alterations in dementiaEllen Vloeberghs
Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium
Behav Neurosci 120:1380-3. 2006..The presence of aggressive disturbances in this valuable mouse model opens perspectives to evaluate aggression-modulating therapies... - Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's diseaseBianca Van Broeck
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Universiteitsplein 1, BE 2610 Antwerpen, Belgium
Neurobiol Aging 29:241-52. 2008..These data support earlier observations of A beta accumulation in the endosomal-lysosomal pathway and the hypothesis that intraneuronal accumulation of A beta could be an important factor in the AD pathogenesis... - Added diagnostic value of CSF biomarkers in differential dementia diagnosisNathalie Le Bastard
Reference Center for Biological Markers of Memory Disorders, Laboratory of Neurochemistry and Behavior, Institute Born Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
Neurobiol Aging 31:1867-76. 2010.... - Actigraphic measurement of agitated behaviour in dementiaGuy Nagels
Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
Int J Geriatr Psychiatry 21:388-93. 2006..74, p<0.0001). Correlations between ctigraphic data and CMAI total scores were moderate but highly significant. CONCLUSION: We conclude that actigraphy is a useful tool to examine agitated behaviour in dementia... - Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse modelsDebby Van Dam
Laboratory of Neurochemistry and Behaviour, Born Bunge Institute, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, B 2610 Wilrijk, Belgium
Neurochem Int 46:409-22. 2005..Transgenic mouse models may be employed as a tool to study early-stage neurochemical changes, which are often not accessible in Alzheimer brain... - The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trialsIra Katz
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA, and Department of Neurology, Memory Clinic, Middelheim Hospital, ZNA, Wilrijk Antwerp, Belgium
Int J Geriatr Psychiatry 22:475-84. 2007..Psychosis of Alzheimer's disease (AD) is a specific component of AD, characterized by delusions, misidentifications, and hallucinations... - Reversal of head drop after discontinuation of olanzapine in a DLB patientMarcel J H Aries
Department of Neurology and Memory Clinic, ZNA Middelheim and ZNA Hoge Beuken, Antwerp, Belgium
Mov Disord 23:1760-2. 2008..Further improvement was achieved after dopaminergic substitution. Clinical and electrophysiological observations might indicate neck extensor myopathy due to axial rigidity or focal neck dystonia, induced by dopamine receptor blockade... - The genetics and neuropathology of frontotemporal lobar degenerationAnne Sieben
Institute Born Bunge, University of Antwerp, Antwerpen, Belgium
Acta Neuropathol 124:353-72. 2012..In this review, we summarize the current state of the rapidly progressing field of genetic, neuropathological and clinical research of this intriguing condition... - The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's diseasePeter Paul De Deyn
Department of Neurology and Memory Clinic, Middelheim General Hospital, ZNA, 2610 Antwerp, Belgium
Int J Geriatr Psychiatry 20:70-9. 2005.... - Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementiaSebastiaan Engelborghs
Department of Neurology and Memory Clinic, Middelheim General Hospital ZNA, Lindendreef 1, 2020 Antwerp, Belgium
Neurobiol Aging 29:1143-59. 2008..New models have been developed, achieving sensitivity, specificity and diagnostic accuracy levels, consistently exceeding 80%... - Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystoniaJessie Theuns
Neurodegenerative Brain Diseases Group, VIB Department of Molecular Genetics, University of Antwerp, Antwerp, Belgium
Mov Disord 27:1451-6. 2012..Autosomal dominant dopa-responsive dystonia (AD-DRD) is caused by a biochemical defect primarily resulting from guanosine triphosphate cyclohydrolase 1 gene (GCH1) mutations. Few families have been reported without mutations in GCH1... - Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 modelDebby Van Dam
Laboratory of Neurochemistry and Behaviour, Born-Bunge Institute, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
Psychopharmacology (Berl) 180:177-90. 2005..The fact that symptomatic intervention was able to diminish cognitive impairment, substantially adds to the validity of the APP23 model as a valuable tool to evaluate future therapeutic approaches... - Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patientsNathalie Le Bastard
Laboratory of Neurochemistry and Behavior, Reference Center for Biological Markers of Memory Disorders, Institute Born Bunge, University of Antwerp, Antwerp, Belgium
J Alzheimers Dis 21:291-301. 2010..CSF biomarker analysis remains superior, although the possible application of longitudinal plasma Abeta measurements as screening tools for dementia remains to be elucidated... - Correlation between actigraphy and nurses' observation of activity in dementiaGuy Nagels
Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
Int J Geriatr Psychiatry 22:84-6. 2007 - Brain-Specific Tryptophan Hydroxylase, TPH2, and 5-HTTLPR are Associated with Frontal Lobe Symptoms in Alzheimer's DiseaseSebastiaan Engelborghs
Department of Neurology and Memory Clinic, Middelheim and Hoge Beuken General Hospitals ZNA, Antwerpen, Belgium Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, University of Antwerp, Antwerpen, Belgium Department of Health Care Sciences, Artesis University College, Antwerpen, Belgium
J Alzheimers Dis 35:67-73. 2013.... - Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's diseaseNathalie Le Bastard
Laboratory of Neurochemistry and Behavior, Reference Center for Biological Markers of Dementia BIODEM, Antwerp, Belgium
J Alzheimers Dis 33:807-22. 2013..Only T-tau increased in AD patients in comparison to controls, which does not preclude its use as a diagnostic marker, nor as a potential pharmacodynamic marker... - Effect of Morris water maze diameter on visual-spatial learning in different mouse strainsDebby Van Dam
Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
Neurobiol Learn Mem 85:164-72. 2006.... - Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment?Hans Debruyne
Department of Neurology and Memory Clinic, Middelheim General Hospital, Antwerp, Belgium
Int J Geriatr Psychiatry 24:556-62. 2009.... - Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's diseasePeter Paul De Deyn
Department of Neurology, Middelheim Hospital, University of Antwerp, Antwerp, Belgium
Int J Geriatr Psychiatry 19:115-26. 2004..5 mg dose was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis and overall behavioral disturbances (NPI/NH, BPRS) and was well tolerated... - Drug discovery in dementia: the role of rodent modelsDebby Van Dam
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
Nat Rev Drug Discov 5:956-70. 2006..Here, we summarize and critically evaluate current rodent models of dementia, and discuss their role in drug discovery and development... - A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate RepeatsJulie van der Zee
Department of Molecular Genetics, VIB, Antwerp, Belgium Institute Born Bunge, University of Antwerp, Antwerp, Belgium
Hum Mutat 34:363-73. 2013..001) with the most common indel creating one long contiguous imperfect G(4) C(2) repeat, which is likely more prone to replication slippage and pathological expansion... - Comparison of extraction methods for peptidomics analysis of mouse brain tissueAnnemie Van Dijck
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, University of Antwerp, Department of Biomedical Sciences, Universiteitsplein 1, B 2610 Wilrijk, Belgium
J Neurosci Methods 197:231-7. 2011..For these reasons, we recommend the use of this protocol in future neuropeptidomics studies... - DLB and PDD: a role for mutations in dementia and Parkinson disease genes?Bram Meeus
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerpen, Belgium
Neurobiol Aging 33:629.e5-629.e18. 2012..They do support the hypothesis of a genetic overlap between members of the Lewy body disease spectrum, but additional genes still have to exist... - Animal models in the drug discovery pipeline for Alzheimer's diseaseDebby Van Dam
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk Antwerp, Belgium
Br J Pharmacol 164:1285-300. 2011.... - Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular diseaseRaf Brouns
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, and Department of Biomedical Sciences, University of Antwerp CDE, Universiteitsplein 1, 2610 Antwerp, Belgium
Stroke 41:863-8. 2010..In this study, we assessed the prevalence of Fabry disease in young patients presenting with cerebrovascular disease in Belgium... - Central administration of obestatin fails to show inhibitory effects on food and water intake in miceAnnemie Van Dijck
Laboratory of Neurochemistry and Behaviour, Institute Born Bunge, University of Antwerp, Department of Biomedical Sciences, Universiteitsplein 1, B 2610 Wilrijk, Belgium
Regul Pept 156:77-82. 2009..Under our experimental conditions, no suppressive effects of obestatin on food or water intake were observed, whereas CRF evoked a significant suppression of food intake, which proves the internal validity of the study design... - Clinical, biochemical and neuroimaging parameters after thrombolytic therapy predict long-term stroke outcomeRaf Brouns
Department of Neurology and Memory Clinic, ZNA Middelheim Hospital, Antwerp, Belgium
Eur Neurol 62:9-15. 2009..We investigated the predictive value of standard neurological evaluation, a commercially available biomarker assay and neuroimaging in the subacute phase for outcome after thrombolytic therapy in ischemic stroke... - GSA: behavioral, histological, electrophysiological and neurochemical effectsAn Torremans
Laboratory of Neurochemistry and Behavior, Born Bunge Foundation, University of Antwerp-Campus Drie Eiken, Universiteitsplein 1, B-2610 Antwerp, Wilrijk, Belgium
Physiol Behav 84:251-64. 2005..Animal models like the 'GSA mouse model' are useful tools for research in this context... - Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian populationAline Verstraeten
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium
Neurobiol Aging 33:1844.e11-3. 2012..Hence, our data do not support a major role for VPS35 variations in the genetic etiology of Lewy body disorders in the Flanders-Belgian population... - Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbancesEllen Vloeberghs
Laboratory of Neurochemistry and Behaviour, Born-Bunge Foundation, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium
Eur J Neurosci 20:2757-66. 2004..This first report of diurnal rhythm disturbances and sundowning-like phenomena in a transgenic mouse model greatly adds to the validity of the APP23 model... - The UBQLN1 polymorphism, UBQ-8i, at 9q22 is not associated with Alzheimer's disease with onset before 70 yearsNathalie Brouwers
Department of Molecular Genetics, Flanders Interuniversity Institute of Biotechnology and Institute Born Bunge, University of Antwerp, Universiteitsplein 1, Belgium
Neurosci Lett 392:72-4. 2006..Our study does not support a major role for this UBQLN1 polymorphism in AD patients with an earlier onset of disease... - The expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (E-NPP1) is correlated with astrocytic tumor gradeIndra Aerts
Department of Biomedical Science, Cellular Biochemistry, Campus Drie Eiken, University of Antwerp, Belgium
Clin Neurol Neurosurg 113:224-9. 2011..In this study, the use of anti-NPP1 antibody in the determination of astrocytic tumor grade is evaluated...